Caladrius Biosciences, Inc. CLBS
We take great care to ensure that the data presented and summarized in this overview for CALADRIUS BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CLBS
Top Purchases
Top Sells
About CLBS
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Insider Transactions at CLBS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2024
|
James Nisco SVP, Fin/Treas, Chief Actg Off |
SELL
Payment of exercise price or tax liability
|
Direct |
1,701
-11.61%
|
$3,402
$2.93 P/Share
|
|
Oct 01
2024
|
James Nisco SVP, Fin/Treas, Chief Actg Off |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+18.38%
|
$6,600
$2.93 P/Share
|
|
Oct 01
2024
|
Kristen K Buck EVP, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,363
-9.22%
|
$12,726
$2.93 P/Share
|
|
Oct 01
2024
|
Kristen K Buck EVP, R&D and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+17.85%
|
$30,000
$2.93 P/Share
|
|
Oct 01
2024
|
David J Mazzo President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
26,964
-11.29%
|
$53,928
$2.93 P/Share
|
|
Oct 01
2024
|
David J Mazzo President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
58,000
+19.54%
|
$116,000
$2.93 P/Share
|
|
Jan 11
2024
|
David J Mazzo President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,026
-0.58%
|
$2,052
$2.99 P/Share
|
|
Jan 10
2024
|
David J Mazzo President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,470
-1.94%
|
$10,410
$3.0 P/Share
|
|
Jan 10
2024
|
Kristen K Buck EVP, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
512
-0.94%
|
$1,536
$3.0 P/Share
|
|
Jan 09
2024
|
David J Mazzo President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,046
-5.16%
|
$60,138
$3.08 P/Share
|
|
Jan 09
2024
|
David J Mazzo President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
94,000
+32.05%
|
-
|
|
Jan 09
2024
|
Kristen K Buck EVP, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,368
-4.58%
|
$16,104
$3.08 P/Share
|
|
Jan 09
2024
|
Kristen K Buck EVP, R&D and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+31.06%
|
-
|
|
Jan 09
2024
|
Cynthia Schwalm Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,480
+28.36%
|
-
|
|
Jan 09
2024
|
Heidi Henson Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,480
+33.04%
|
-
|
|
Jan 09
2024
|
Steven M Klosk Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,480
+28.21%
|
-
|
|
Jan 09
2024
|
Mohammad Azab Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,480
+24.92%
|
-
|
|
Jan 09
2024
|
Gregory B Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,480
+28.28%
|
-
|
|
Sep 01
2023
|
Kristen K Buck EVP, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,908
-8.12%
|
$5,816
$2.18 P/Share
|
|
Jan 13
2023
|
David J Mazzo President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-0.41%
|
$1,191
$3.65 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 295K shares |
|---|
| Payment of exercise price or tax liability | 65.5K shares |
|---|